Equity research analysts covering SOPHiA GENETICS (NASDAQ: SOPH) maintain consensus forecasts pointing toward moderate long-term growth, driven by expanding hospital adoption of its decentralized clinical analytics software, though near-term valuations remain tied to cash-flow milestones and SaaS revenue expansion.